| Schedule of Line of Credit Facilities |
The following tables summarize noteworthy information related to the Credit Facility:
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, |
|
2023 |
|
2022 |
| Commitment amount |
$ |
180,000
|
|
|
$ |
180,000 |
|
| Borrowings outstanding at cost |
$ |
35,200
|
|
|
$ |
— |
|
Availability(A)
|
$ |
144,800
|
|
|
$ |
180,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended March 31 |
|
2023 |
|
2022 |
|
2021 |
Weighted-average borrowings outstanding |
$ |
16,186
|
|
|
$ |
18,051 |
|
|
$ |
82,632 |
|
Effective interest rate(B)
|
17.3
|
% |
|
12.5 |
% |
|
4.3 |
% |
| Commitment (unused) fees incurred |
$ |
1,655
|
|
|
$ |
1,641 |
|
|
$ |
819 |
|
(A)Availability is subject to various constraints, characteristics, and applicable advance rates based on collateral quality under the Credit Facility, which equated to an adjusted availability of $144.8 million and $180.0 million as of March 31, 2023 and 2022, respectively.
(B)Excludes the impact of deferred financing costs and includes unused commitment fees.
|
| Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation |
The following tables provide relevant information and disclosures about the Credit Facility as of and for the years ended March 31, 2023 and 2022, as required by ASC 820:
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 – Borrowings |
|
Recurring Fair Value Measurements Reported in
Consolidated Statements of Assets and Liabilities
Using Significant Unobservable Inputs (Level 3)
As of March 31,
|
|
2023 |
|
2022 |
Credit Facility |
$ |
35,171 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
Fair Value Measurements of Borrowings Using Significant Unobservable Inputs (Level 3)
Reported in Consolidated Statements of Assets and Liabilities
|
|
Credit Facility |
Year ended March 31, 2023: |
|
Fair value at March 31, 2022 |
$ |
— |
|
Borrowings |
102,500 |
|
Repayments |
(67,300) |
|
| Unrealized depreciation |
(29) |
|
Fair value at March 31, 2023 |
$ |
35,171
|
|
|
|
Year ended March 31, 2022: |
|
Fair value at March 31, 2021 |
$ |
22,400 |
|
Borrowings |
111,700 |
|
Repayments |
(134,100) |
|
Fair value at March 31, 2022 |
$ |
—
|
|
|
| Schedule of Debt |
The following tables summarizes our 2026 Notes and 2028 Notes as of March 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2023: |
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Ticker
Symbol |
|
Date Issued |
|
Maturity Date(A)
|
|
Interest
Rate |
|
Notes
Outstanding |
|
Principal
Amount per
Note |
|
Aggregate
Principal Amount |
| 2026 Notes |
|
GAINN |
|
March 2, 2021 |
|
May 1, 2026 |
|
5.00% |
|
5,117,500 |
|
$ |
25.00 |
|
|
$ |
127,938
|
|
| 2028 Notes |
|
GAINZ |
|
August 18, 2021 |
|
November 1, 2028 |
|
4.875% |
|
5,382,000 |
|
$ |
25.00 |
|
|
134,550
|
|
Notes payable, gross(B)
|
|
10,499,500 |
|
|
|
262,488
|
|
| Less: Unamortized Discounts |
|
|
|
|
|
(5,052) |
|
Notes payable, net(C)
|
|
|
|
|
|
$ |
257,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2022: |
|
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Ticker
Symbol |
|
Date Issued |
|
Maturity Date(A)
|
|
Interest
Rate |
|
Notes
Outstanding |
|
Principal
Amount per
Note |
|
Aggregate
Principal Amount |
| 2026 Notes |
|
GAINN |
|
March 2, 2021 |
|
May 1, 2026 |
|
5.00% |
|
5,117,500 |
|
$ |
25.00 |
|
|
$ |
127,938
|
|
| 2028 Notes |
|
GAINZ |
|
August 18, 2021 |
|
November 1, 2028 |
|
4.875% |
|
5,382,000 |
|
$ |
25.00 |
|
|
134,550
|
|
Notes payable, gross(B)
|
|
10,499,500 |
|
|
|
262,488
|
|
| Less: Unamortized Discounts |
|
|
|
|
|
(6,236) |
|
Notes payable, net(C)
|
|
|
|
|
|
$ |
256,252
|
|
(A)The 2026 Notes can be redeemed at our option at any time on or after May 1, 2023. The 2028 Notes can be redeemed at our option at any time on or after November 1, 2023.
(B)As of March 31, 2023 and 2022, asset coverage on our senior securities representing indebtedness, calculated pursuant to Sections 18 and 61 of the 1940 Act, was 244.7% and 252.9%, respectively.
(C)Reflected as a line item on our accompanying Consolidated Statements of Assets and Liabilities.
|